Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 748

Similar articles for PubMed (Select 16720680)

1.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N.

J Clin Oncol. 2006 Aug 10;24(23):3726-34. Epub 2006 May 23.

2.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG.

J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82.

5.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N.

J Natl Cancer Inst Monogr. 2001;(30):62-6.

PMID:
11773294
6.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N.

N Engl J Med. 2004 Dec 30;351(27):2817-26. Epub 2004 Dec 10.

7.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, DeschĂȘnes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL.

J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42.

8.

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L.

J Clin Oncol. 2000 Oct 15;18(20):3471-9.

PMID:
11032587
9.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America.

Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.

11.

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB.

J Clin Oncol. 2001 Feb 15;19(4):931-42.

PMID:
11181655
12.

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.

Clin Cancer Res. 2005 May 1;11(9):3315-9.

13.

The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.

Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB, Goldstein LJ.

Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):669-77.

PMID:
8690632
14.

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.

Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B.

Cancer. 2008 Feb 15;112(4):731-6.

15.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N.

J Natl Cancer Inst. 2001 Jan 17;93(2):112-20.

16.
17.

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G.

J Clin Oncol. 1999 Jun;17(6):1701-9.

PMID:
10561206
18.

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70.

19.

Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.

Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M; German Adjuvant Breast Cancer Group.

J Clin Oncol. 2005 Nov 1;23(31):7842-8.

20.

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Hornberger J, Cosler LE, Lyman GH.

Am J Manag Care. 2005 May;11(5):313-24. Erratum in: Am J Manag Care. 2005 Aug;11(8):476.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk